'Epigenetic Therapies and Technologies Market Will Reach $2,518 Million in 2013' Predicts New Visiongain Report

LONDON, January 22, 2013 /PRNewswire/ --

A new report by Visiongain predicts that the overall world market for epigenetic therapies and technologies will be worth $2,518m in 2013. Between 2011 and 2017, the global market will grow with a CAGR of over 10%. The launch of new products in all market sectors will drive growth during this decade. Those findings, among others, appear in Epigenetic Therapies and Technologies: World Market Prospects 2013-2023, published in January 2013. Visiongain is a business information provider based in London, UK.

Throughout the 10-year forecast period, epigenetic therapies will be the largest sector of the world epigenetics market, accounting for more than half of revenues in 2023. In 2011, Celgene's Vidaza led the market, with revenue of $705m. Patent expiries and generic launches will affect three of the four currently-marketed therapies by the middle of this decade, visiongain's report predicts. Growth in the sector will be driven by the launch of new drugs beyond 2014. Two new epigenetic therapies - TopoTarget/Spectrum Pharmaceuticals' belinostat and Novartis' Faridak will reach major markets in that year.

The epigenetic diagnostics submarket will grow fastest between 2013 and 2023. More than ten epigenetic-based diagnostics are marketed in major developed markets, although revenues for these products are low. The launch of in vitro diagnostic tests (IVDs) and companion diagnostics for cancer indications, such as Epigenomics' Epi proColon 2.0 in the US, will drive growth in this sector to 2023. Strong growth is also forecast for the epigenetic technologies submarket, driven by increased demand for research tools worldwide, with revenues reaching more than $1bn by 2017.

Richard Lang, a pharmaceutical industry analyst for visiongain, said: "Collaborations between the pharmaceutical industry and academia have led to rapid growth in the understanding of the role of epigenetics in disease. Continued collaboration in global projects mapping epigenomes will lead to further opportunities in drug discovery and diagnostic biomarker development. Licensing deals between multinational pharmaceutical players and small biotechs will accelerate promising drug candidates into late-stage trials during this decade.

"In 2011, the US and Europe dominated the market, accounting for more than 75% of global revenues. The US is the only major national market where all four epigenetic therapies are approved. Emerging markets currently play only a minor role in the global epigenetics industry. However, rising drug sales and greater involvement in global research collaborations will lead to rising revenues there. By 2023, revenues for epigenetic therapies and technologies in the BRIC nations will total $255m."

Epigenetic Therapies and Technologies: World Market Prospects 2013-2023 provides quantitative and qualitative analyses of the epigenetics market. It shows revenue forecasts to 2023 for the overall world market, submarkets, leading marketed and pipeline therapies, and prominent national and regional markets. It also identifies and discusses future trends in epigenetic research and product development. The study adds to visiongain's portfolio of analytical reports covering innovative and emerging sectors of the pharmaceutical industry.

For sample pages and further information concerning the visiongainEpigenetic Therapies and Technologies: World Market Prospects 2013-2023 report please visit: http://www.visiongain.com/Report/961/Epigenetic-Therapies-and-Technologies-World-Market-Prospects-2013-2023

Companies Listed
4SC
4SC Discovery (part of 4SC)
Abbott Laboratories (AbbVie)
Accelerate Brain Cancer Cure
Accium BioSciences
Acetylon Pharmaceuticals
Active Motif
Agence Nationale de la Recherche (ANR) [France]
Agilent Technologies
Agios
Allos Therapeutics
American Cancer Society
Amgen
Applied Biosystems (part of Life Technologies)
ARUP Laboratories
Astellas Venture Management
Astex Pharmaceuticals
AstraZeneca
Aton Pharma (part of Merck & Co.)
Australian Alliance for Epigenetics
Bayer
BellBrook Labs
BGI (formerly Beijing Genomics Institute)
Biogen Idec
Boehringer Mannheim (part of Roche)
Boston Children's Hospital
Brabraham Institute [UK]
Bundesministerium für Bildung und Forschung (BMBF) [Germany]
Cambridge Institute for Medical Research
Canadian Epigenetics, Environment and Health Consortium
Canadian Institutes for Health Research (CIHR)
CanAm Bioresearch
Cancer Research Technology
Cancer Research UK
Celgene
CellCentric
Celleron Therapeutics
Cellzome (part of GSK)
Center for Genome Science [South Korea]
Centers for Medicare and Medicaid Services (CMS)
Centocor Research & Development (part of J&J)
Centre de Regulació Genòmica [Spain]
Centre for Addiction and Mental Health [Canada]
Centre for Genomic Regulation [Barcelona]
Centre National de la Recherche Scientifique (CNRS)
Chiron (part of Novartis)
Chroma Therapeutics
Clavis Pharma
Companion Dx
Constellation Pharmaceuticals
Cornell University
Crelux
Curis
Dana-Farber Cancer Institute
Department of Biotechnology [India]
Diagenode
DiscoveRx
Domainex
Durviz
Eisai
Eli Lilly
Elixir Pharmaceuticals
EMA Committee for Medicinal Products for Human Use (CHMP)
EMD Millipore (part of Merck KGaA)
EnVivo Pharmaceuticals
EpigenDx
Epigenetics Dream Team
Epigenomics
Epigentek
Epiontis
EpiTherapeutics
Epizyme
European Commission
European Institute of Oncology (IEO)
European Medicines Agency (EMA)
European Patent Office
Exact Sciences
Flagship Biosciences
Food and Drug Administration (FDA) [US]
Friedreich's Ataxia Research Alliance (FARA)
Genentech (part of Roche)
Genomic Health
Genpathway (part of Active Motif)
Genzyme (part of Sanofi)
Gloucester Pharmaceuticals (part of Celgene)
Go FAR (Friedreich's Ataxia Research)
GSK
Harvard University
Health Canada
Helicos BioSciences
Hewlett-Packard
Ignyta
IkerChem
Imperial College London
Indian Institute of Science Education and Research
Institute of Cancer Research [UK]
Intelligent Bio-Systems (part of Qiagen)
International Human Epigenome Consortium (IHEC)
Italfarmaco
J&J
Janssen-Cilag
Japan Science and Technology Agency (JST)
Japanese Society for Epigenetics
John Hopkins University
Karus Therapeutics
King's College London (KCL)
LabCorp
Leukemia and Lymphoma Society (LLS)
Life Technologies
Louis Pasteur University of Strasbourg
Lundbeckfond Ventures
M.D. Anderson Cancer Center
Macmillan Cancer Support
Massachusetts General Hospital
Mayo Clinic
McGill University
MDxHealth
MEI Pharma
Memorial Sloan-Kettering Cancer Center
Merck & Co.
Merck KGaA
Merck Serono Ventures
MethylGene
MGI Pharma (part of Eisai)
Michael J. Fox Foundation
Microgenics (part of Boehringer Mannheim)
Millennium Pharmaceuticals
Ministry of Health, Labor and Welfare (MHLW) [Japan]
MiReven
Mirna Therapeutics
Mitomics
Mount Sinai Medical Center
Multiple Myeloma Research Foundation
Muscular Dystrophy Association (MDA)
Myeloma UK
Myriad Genetics
National Ataxia Foundation (NAF)
National Cancer Institute (NCI) [US]
National Health Service (NHS) [UK]
National Human Genome Research Institute (NHGRI) [US]
National Institute for Health and Clinical Excellence (NICE) [UK]
National Institute for Mental Health (NIMH) [US]
National Institutes of Health (NIH) [US]
NIH Roadmap Epigenomics Mapping Consortium [US]
Nippon Shinyaku
Novartis
Novo Nordisk
Novo Seeds
Nycomed
Odyssey Molecular
Onyx Pharmaceuticals
Orion Genomics
Oryzon Genomics
Otsuka Pharmaceutical
Pacific Biosciences
Pfizer
Pfizer Venture Investments
Pharmacyclics
Pharmion (part of Celgene)
PLUS Diagnostics
Predictive Biosciences
PrognosDx Health
Qiagen
Quest Diagnostics
Regulus Therapeutics
Repligen
Resverlogix
Roadmap Epigenomics Mapping Consortium [US]
Roche
Roche NimbleGen (part of Roche)
S*BIO (part of Chiron)
SABiosciences (part of Qiagen)
Salarius Pharmaceuticals
Sanofi
Santaris Pharma
Scottish Medicines Consortium (SMC)
Seed Capital
Servier
Shape Pharmaceuticals
Siena Biotech
Sigma-Aldrich
Spectrum Pharmaceuticals
Structural Genomics Consortium (SGC)
Swiss Life
Syndax Pharmaceuticals
Sysmex
Taiho Pharmaceutical
Takeda
Takeda Ventures
Technology Strategy Board (TSB) [UK]
Tensha Therapeutics
The Automation Partnership (now TAP Biosystems)
The Pharmaceutical Research and Manufacturers of America (PhRMA)
Thomas Jefferson University
TopoTarget
University College London (UCL)
University of Birmingham
University of California, Los Angeles (UCLA)
University of California, San Diego
University of Cambridge
University of Chicago
University of Copenhagen
University of Edinburgh
University of Liège
University of North Carolina
University of Nottingham
University of Oxford
University of Southampton
University of Southern California
University of the Basque Country
University of Toronto
University of Utah
University of Wuerzburg
Ventana Medical Systems (part of Roche)
Wellcome Trust
Wistar Institute
World Health Organization (WHO)
Yakult Honsha
ZoBio 

About visiongain

Visiongain is one of the fastest growing and most innovative independent media companies in Europe. Based in London, UK, visiongain produces a host of business-2-business conferences, newsletters, management reports and e-zines focusing on the Energy, Telecoms, Pharmaceutical, Defence, Materials sectors.

Visiongain publishes reports produced by its in-house analysts, who are qualified experts in their field. Visiongain has firmly established itself as the first port-of-call for the business professional, who needs independent, high quality, original material to rely and depend on.

If you are interested in a more detailed overview of this report, please send an e-mail to sara.peerun@visiongainglobal.com or call her on +44(0)207-336-6100